drugset / Trial / NCT05956600

An Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms

NCT05956600

NaSingle-groupOpen-labelTreatment

Summary

The objectives of this study are to evaluate the safety and efficacy of Amisulpride as an add-on therapy or alternative monotherapy in treating patients with schizophrenia or schizoaffective disorder who have treatment-resistant positive symptoms and who are not eligible for treatment with clozapine due to intolerance, failure from a prior clozapine trial, or unwillingness to be treated with clozapine.

Timeline

Start
2023-11
Primary completion
2025-11
Completion
2026-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule Oral